Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery
- 1 October 2002
- journal article
- case report
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 16 (5) , 615-616
- https://doi.org/10.1053/jcan.2002.126927
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One Single Dose of Activated Recombinant Factor VIIAnesthesia & Analgesia, 2001
- The Regulation of the Factor VII-Dependent Coagulation Pathway: Rationale for the Effectiveness of Recombinant Factor VIIa in Refractory Bleeding DisordersSeminars in Thrombosis and Hemostasis, 2000
- NovoSeven® as a universal haemostatic agentBlood Coagulation & Fibrinolysis, 2000
- Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven®)Blood Coagulation & Fibrinolysis, 2000
- Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgeryBlood Coagulation & Fibrinolysis, 2000
- Reexploration for Hemorrhage Following Coronary Artery Bypass GraftingIncidence and Risk FactorsArchives of Surgery, 1998
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997
- The Procoagulant Response to InjuryThe Annals of Thoracic Surgery, 1997
- Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operationsThe Journal of Thoracic and Cardiovascular Surgery, 1996